Published in Gut on July 01, 2005
Importance of nutrition in inflammatory bowel disease. World J Gastroenterol (2009) 0.96
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology (1999) 5.03
Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology (2001) 4.44
Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 4.40
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 3.80
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol (1999) 2.93
Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology (1999) 2.37
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci (2000) 2.26
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol (2004) 2.13
Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology (2004) 1.87
DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology (2004) 1.78
Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis (2002) 1.70
Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol (2003) 1.51
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol (2001) 1.43
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis (2002) 1.15
The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat. Scand J Gastroenterol (1993) 1.15
Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol (2002) 1.15
Intestinal epithelial tight junctions as targets for enteric bacteria-derived toxins. Adv Drug Deliv Rev (2004) 1.03
Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut (2005) 0.97
Role of microecology in chronic inflammatory bowel diseases. Eur J Clin Nutr (2002) 0.94
Intestinal epithelial pathobiology: past, present and future. Best Pract Res Clin Gastroenterol (2002) 0.93
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med (1996) 3.47
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet (1981) 2.02
Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol (1994) 1.69
Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol (1999) 1.62
Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis (2005) 1.61
Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol (2008) 1.61
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther (1994) 1.59
Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int (2001) 1.51
The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther (2007) 1.49
Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 1.49
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis (2007) 1.43
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol (2001) 1.43
Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther (2002) 1.41
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology (1986) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2005) 1.25
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
[Epidemiological study on intestinal inflammatory diseases in the Province of Bologna]. G Clin Med (1977) 1.21
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology (1999) 1.16
Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol (1999) 1.16
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut (1985) 1.15
Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol (2002) 1.15
Prostaglandins, indomethacin, and ulcerative colitis. Gastroenterology (1980) 1.11
Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum (2005) 1.09
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther (2002) 1.07
Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci (1994) 1.05
Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol (2003) 1.04
Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther (2002) 1.04
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther (2009) 1.03
Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol (1998) 1.03
Rectal cell proliferation and colon cancer risk in ulcerative colitis. Cancer Res (1990) 1.02
Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother (2002) 1.02
Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol (1992) 1.01
Different patterns of intestinal transit time and anorectal motility in painful and painless chronic constipation. Gut (1984) 0.98
p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet (1994) 0.98
Clinical course of ulcerative colitis in Italy. Digestion (1980) 0.97
Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther (2008) 0.97
Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol (2000) 0.97
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis (2001) 0.96
A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion (1984) 0.96
Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci (1991) 0.95
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis (2001) 0.94
Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol (1986) 0.93
Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther (2003) 0.93
CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Tech Coloproctol (2006) 0.93
Improved method for the isolation and cultivation of human scalp dermal papilla cells. J Invest Dermatol (1992) 0.92
Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol (2005) 0.91
Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther (2001) 0.91
Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci (2000) 0.91
Specificity of leucocyte migration inhibition test in coeliac disease. A reassessment using different gluten subfractions. Clin Exp Immunol (1985) 0.90
New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. Neurogastroenterol Motil (2012) 0.90
Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci (1992) 0.90
Salicylate other than 5-aminosalicylic acid ineffective in ulcerative colitis. Lancet (1978) 0.89
Implications of antioxidant enzymes in human gastric neoplasms. Int J Mol Med (2009) 0.89
Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2010) 0.89
Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 0.88
Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther (1997) 0.87
Assessment of nutritional status in Crohn's disease in remission or low activity. Hepatogastroenterology (1984) 0.87
Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am J Gastroenterol (2001) 0.86
Review article: treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther (2002) 0.86
Interleukin 1 in ulcerative colitis. Gut (1991) 0.86
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum (1998) 0.85
Interleukin 1 beta (IL-1 beta) release from fresh and cultured colonic mucosa in patients with ulcerative colitis (UC). Agents Actions (1992) 0.85
Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment Pharmacol Ther (1997) 0.85
Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. Dig Dis Sci (1997) 0.85
Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. Dig Dis Sci (1994) 0.85
A possible mechanism of action of sulfasalazine and 5-aminosalicylic acid in inflammatory bowel diseases: interaction with oxygen free radicals. Gastroenterology (1985) 0.85